Antiviral prophylaxis for varicella zoster in immunocompromised patients (excluding haematological malignancies)
Referencias
Additional references
Adler AL, Casper C, Boeckh M, Heath J, Zerr DM. An outbreak of varicella with likely breakthrough disease in a population of pediatric cancer patients. Infection Control and Hospital Epidemiology 2008;29(9):866‐70.
Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA. Long‐term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double‐blind placebo‐controlled study. Blood 2006;107(5):1800‐5.
Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. Journal of Infectious Diseases 2008;197(Suppl 2):237‐41.
Diaz‐Mitoma F, Sibbald RG, Shafran SD, Boon R, Saltzman RL, for the Collaborative Famciclovir Genital Herpes Research Group. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Journal of the American Medical Association 1998;280(10):887‐92.
Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Fife KH, Warren TJ, Justus SE, Heitman CK, HS2100275 Study Team. An international, randomized, double‐blind, placebo‐controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients. Sexually Transmitted Diseases 2008;35(7):668‐73.
Gilden D. Varicella zoster virus and central nervous system syndromes. Herpes 2004;11(Suppl 2):89A‐94A.
Gourishankara S, McDermida JC, Jhangric GS, Preiksaitisa JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. American Journal of Transplantation 2004;4(1):108‐15.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0 [updated February 2008]. The Cochrane Collaboration (Available from www.cochrane‐handbook.org). Chichester, UK: Wiley‐Blackwell, 2008.
Hodson EM, Craig JC, Strippoli GFM, Webster AC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD003774.pub3]
Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD004946.pub2]
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: Wiley‐Blackwell, 2008.
Ljungman P, Wilczek H, Gahrton G, Gustavsson A, Lundgren G, Lonnqvist B, et al. Long‐term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplantation 1986;1(2):185‐92.
Reynolds MA, Watson BM, Plott‐Adams KK, Jumaan AO, Galil K, Maupin TJ, et al. Epidemiology of Varicella Hospitalizationsin the United States, 1995–2005. Journal of Infectious Diseases 2008;197(Suppl 2):120‐6.
Selby PJ, Powles RL, Easton D, Perren TJ, Stolle K, Jameson B, et al. The prophylactic role of intravenous and long‐term oral acyclovir after allogeneic bone marrow transplantation. British Journal of Cancer 1989;59(3):434‐8.
Trelle S, Bohlius J, Skoetz N, Schwarzer G, Cornely O, Engert A. Antiviral agents for prophylaxis of herpesviridae infections in patients with haematological malignancies. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD004628]
Weller TH. Varicella‐zoster virus:History, perspectives, and evolving concerns. Neurology 1995;45(12 Suppl 8):9‐10.
